Lopinavir/ritonavir

A review for 2011

Robyn Teply, Mark Goodman, Christopher J. Destache

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Ritonavir-boosted lopinavir (LPV/r) is a boosted protease inhibitor (PI) combination used as an alternative agent in the management of the human immunodeficiency virus (HIV). HIV treatment consists of combinations of classes of medications with complementing mechanisms of action. Protease inhibitor-based therapy is one of the mainstays of therapy. Ritonavir-boosted lopinavir can be dosed once- or twice-daily based on previous antiretroviral therapy, patient characteristics, and concomitant medications. It is currently available as an oral solution or tablet formulation and can be given without regard to food if given as a tablet. Lopinavir is extensively metabolized via the cytochrome (CYP) P450 3A4 and 3A5 hepatic isoenzymes and ritonavir is a potent inhibitor of CYP34A. Co-administration of low-dose ritonavir leads to increased plasma concentrations of lopinavir. There is potential for numerous drug-drug interactions when additional medications are administered. Clinical trials have been reported previously demonstrating the safety and efficacy of LPV/r in children, adolescents and adults and it is readily used throughout these populations. Current clinical trials are focused on examining the efficacy and toxicity of boosted-PI monotherapy as a treatment option in previously suppressed adults.

Original languageEnglish
Pages (from-to)93-102
Number of pages10
JournalClinical Medicine Insights: Therapeutics
Volume3
DOIs
StatePublished - 2011

Fingerprint

Lopinavir
Ritonavir
Protease Inhibitors
Cytochrome P-450 CYP3A
Tablets
Clinical Trials
HIV
Therapeutics
Drug Interactions
Isoenzymes
Safety
Food
Liver
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pharmaceutical Science
  • Pharmacology

Cite this

Lopinavir/ritonavir : A review for 2011. / Teply, Robyn; Goodman, Mark; Destache, Christopher J.

In: Clinical Medicine Insights: Therapeutics, Vol. 3, 2011, p. 93-102.

Research output: Contribution to journalReview article

@article{870a9d17c6af47929d10ce87e24dda85,
title = "Lopinavir/ritonavir: A review for 2011",
abstract = "Ritonavir-boosted lopinavir (LPV/r) is a boosted protease inhibitor (PI) combination used as an alternative agent in the management of the human immunodeficiency virus (HIV). HIV treatment consists of combinations of classes of medications with complementing mechanisms of action. Protease inhibitor-based therapy is one of the mainstays of therapy. Ritonavir-boosted lopinavir can be dosed once- or twice-daily based on previous antiretroviral therapy, patient characteristics, and concomitant medications. It is currently available as an oral solution or tablet formulation and can be given without regard to food if given as a tablet. Lopinavir is extensively metabolized via the cytochrome (CYP) P450 3A4 and 3A5 hepatic isoenzymes and ritonavir is a potent inhibitor of CYP34A. Co-administration of low-dose ritonavir leads to increased plasma concentrations of lopinavir. There is potential for numerous drug-drug interactions when additional medications are administered. Clinical trials have been reported previously demonstrating the safety and efficacy of LPV/r in children, adolescents and adults and it is readily used throughout these populations. Current clinical trials are focused on examining the efficacy and toxicity of boosted-PI monotherapy as a treatment option in previously suppressed adults.",
author = "Robyn Teply and Mark Goodman and Destache, {Christopher J.}",
year = "2011",
doi = "10.4137/CMT.S2018",
language = "English",
volume = "3",
pages = "93--102",
journal = "Clinical Medicine Insights: Therapeutics",
issn = "1179-559X",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Lopinavir/ritonavir

T2 - A review for 2011

AU - Teply, Robyn

AU - Goodman, Mark

AU - Destache, Christopher J.

PY - 2011

Y1 - 2011

N2 - Ritonavir-boosted lopinavir (LPV/r) is a boosted protease inhibitor (PI) combination used as an alternative agent in the management of the human immunodeficiency virus (HIV). HIV treatment consists of combinations of classes of medications with complementing mechanisms of action. Protease inhibitor-based therapy is one of the mainstays of therapy. Ritonavir-boosted lopinavir can be dosed once- or twice-daily based on previous antiretroviral therapy, patient characteristics, and concomitant medications. It is currently available as an oral solution or tablet formulation and can be given without regard to food if given as a tablet. Lopinavir is extensively metabolized via the cytochrome (CYP) P450 3A4 and 3A5 hepatic isoenzymes and ritonavir is a potent inhibitor of CYP34A. Co-administration of low-dose ritonavir leads to increased plasma concentrations of lopinavir. There is potential for numerous drug-drug interactions when additional medications are administered. Clinical trials have been reported previously demonstrating the safety and efficacy of LPV/r in children, adolescents and adults and it is readily used throughout these populations. Current clinical trials are focused on examining the efficacy and toxicity of boosted-PI monotherapy as a treatment option in previously suppressed adults.

AB - Ritonavir-boosted lopinavir (LPV/r) is a boosted protease inhibitor (PI) combination used as an alternative agent in the management of the human immunodeficiency virus (HIV). HIV treatment consists of combinations of classes of medications with complementing mechanisms of action. Protease inhibitor-based therapy is one of the mainstays of therapy. Ritonavir-boosted lopinavir can be dosed once- or twice-daily based on previous antiretroviral therapy, patient characteristics, and concomitant medications. It is currently available as an oral solution or tablet formulation and can be given without regard to food if given as a tablet. Lopinavir is extensively metabolized via the cytochrome (CYP) P450 3A4 and 3A5 hepatic isoenzymes and ritonavir is a potent inhibitor of CYP34A. Co-administration of low-dose ritonavir leads to increased plasma concentrations of lopinavir. There is potential for numerous drug-drug interactions when additional medications are administered. Clinical trials have been reported previously demonstrating the safety and efficacy of LPV/r in children, adolescents and adults and it is readily used throughout these populations. Current clinical trials are focused on examining the efficacy and toxicity of boosted-PI monotherapy as a treatment option in previously suppressed adults.

UR - http://www.scopus.com/inward/record.url?scp=79953007850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953007850&partnerID=8YFLogxK

U2 - 10.4137/CMT.S2018

DO - 10.4137/CMT.S2018

M3 - Review article

VL - 3

SP - 93

EP - 102

JO - Clinical Medicine Insights: Therapeutics

JF - Clinical Medicine Insights: Therapeutics

SN - 1179-559X

ER -